SA-58 is under clinical development by Sinovac Biotech and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how SA-58’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SA-58 overview

SA-58 is under development for the treatment of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and omicron mutants. It is administered through intranasal route in the form of spray. It acts by targteting new coronavirus spike protein.

Sinovac Biotech overview

Sinovac Biotech is a biopharmaceutical company. The company essentially focuses on the research, development, manufacturing, and commercialization of human vaccines and related products with focus on disease prevention and control. Its product portfolio includes vaccines for COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps. Sinovac Biotech‘s vaccines are used in the healthcare industry for disease prevention and control. While the company primarily operates in China, it also supplies vaccines to other countries in Asia, Africa, the Mediterranean region, and Central America. Sinovac Biotech is headquartered in Beijing, China.

For a complete picture of SA-58’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.